Harbor Investment Advisory LLC Trims Stake in Stryker Corporation $SYK

Harbor Investment Advisory LLC reduced its holdings in Stryker Corporation (NYSE:SYK) by 26.6% during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,474 shares of the medical technology company’s stock after selling 1,985 shares during the quarter. Harbor Investment Advisory LLC’s holdings in Stryker were worth $1,799,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the business. Brighton Jones LLC grew its stake in Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after buying an additional 609 shares in the last quarter. Schnieders Capital Management LLC. purchased a new stake in shares of Stryker during the 2nd quarter valued at $205,000. Marshall Wace LLP lifted its holdings in shares of Stryker by 107.9% during the 2nd quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock worth $2,255,000 after acquiring an additional 77,831 shares during the last quarter. Nebula Research & Development LLC bought a new stake in shares of Stryker during the 2nd quarter worth $219,000. Finally, HUB Investment Partners LLC purchased a new position in Stryker in the second quarter worth $253,000. Institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

SYK stock opened at $314.81 on Wednesday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $404.87. The firm’s fifty day moving average is $310.38 and its 200 day moving average is $339.43. The firm has a market cap of $120.69 billion, a P/E ratio of 36.44, a P/E/G ratio of 2.12 and a beta of 0.78.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The business had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.Stryker’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Research analysts predict that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be issued a $0.88 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker’s payout ratio is currently 40.74%.

Insider Transactions at Stryker

In other news, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP M Kathryn Fink sold 5,220 shares of the stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $283.85, for a total value of $1,481,697.00. Following the sale, the vice president owned 13,137 shares of the company’s stock, valued at $3,728,937.45. This represents a 28.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 323,264 shares of company stock worth $100,659,489. Company insiders own 4.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on SYK shares. Wall Street Zen cut Stryker from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Truist Financial reaffirmed a “hold” rating and set a $330.00 price target (down from $380.00) on shares of Stryker in a research note on Monday, May 4th. Barclays cut their price objective on Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a report on Monday, May 4th. Needham & Company LLC reduced their price objective on Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Finally, BTIG Research decreased their price objective on Stryker from $397.00 to $379.00 and set a “buy” rating on the stock in a report on Friday, May 1st. Sixteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $395.33.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.